FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammographyBusiness Wire • 06/23/23
Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 DiabetesBusiness Wire • 06/22/23
Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas TherapeuticsBusiness Wire • 06/06/23
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncologyBusiness Wire • 06/01/23
Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual MeetingBusiness Wire • 05/25/23
Bayer launches Seeing Red campaign around the treatment of Heavy Menstrual Bleeding (HMB)Business Wire • 05/16/23
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified CancerBusiness Wire • 05/16/23
Bayer Receives U.S. FDA Fast Track Designation for asundexian Atrial Fibrillation ProgramBusiness Wire • 05/16/23
Bayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'Seeking Alpha • 05/02/23